PPARG and glioblastoma: Considering this, we asked (1), whether a clinically applicable PPARγ antagonist (GW‐9662) would suppress tumor cell growth in neuroblastoma and glioblastoma cells, and (2), whether it would affect the expression of genes associated with Wnt/β‐catenin which are known to play an important role in GBM pathogenesis (Figure 1, Figure S1).